Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

780

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Complicated Urinary Tract Infection Including Acute Pyelonephritis

Interventions

DRUG

Combination of Imipenem/Cilastatin and XNW4107

Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection

DRUG

Meropenem

Meropenem 1g for injection

Trial Locations (1)

University of Maryland Medical Center, Baltimore